Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 1997

View Archived Issues

Oral and nasal sumatriptan studied for migraine

Clinical results presented for Knoll's PEG-hirudin

Clinical pharmacokinetics and safety reported for Sankyo's MAO-A inhibitor

Clinical pharmacokinetics and bradycardic activity of S-16257

Pentoxifylline demonstrates gastroprotective effects in patient study

First combination anti-HIV drug approved in U.S.

Symphony discloses AMPA antagonists

Inhibitors of sCD23 production developed at SmithKline Beecham

Zeneca presents new antibacterials active against resistant pathogens

Na+/K+-exchange inhibitors from Fujisawa

Rhone-Poulenc Rorer discloses new AMPA/NMDA receptor antagonists

Antiviral thienoxazinones prepared at SKB

LY-333334: new bone anabolic agent from Lilly

PathoGenesis presents new antimycobacterial agents

Alza to market IVAX urology products in U.S., Canada

Intron A/ribavirin combination for HCV: preliminary phase III results

Seroquel cleared for marketing in U.S.

Amgen to emphasize calcimimetics program; preliminary phase II results reported for R-568

LF-08-0299 both prevents and reverses kidney rejection in dogs

Patient recruitment for verteporfin phase III trials exceeds goals

New class of antifungal agents developed at Glaxo Wellcome

SNX-111 study in head trauma resumed

Bayer evaluates novel heteroaryl oxazolidinones

Pfizer seeks U.S. and European approval for Viagra

Techniclone submits IND for malignant glioma

Clinical results on neuraminidase inhibitor presented at ICAAC

Inex seeks Canadian approval to commence Onco TCS trials for lymphoma

Warner-Lambert reports dihydropyrone HIV protease inhibitors

Canadian regulatory review of modafinil continues

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...